Post Categories
Conference Report: EAACI Annual Conference in Lisbon, Portugal on June 1 – 5, 2019
June 17, 2019
Professor Zuzana Diamant, MD PhD, Executive Medical and Scientific Director of Respiratory & Allergy at QPS Netherlands, and EAACI Asthma Section Chair 2017-2019, lectured…
Power Women in Business Development at QPS Netherlands
June 13, 2019
Two power women currently ‘man’ the Business Development (BD) department at QPS Netherlands, in close collaboration with the Head of BD, Edwin van Vulpen,…
Inflammatory Disease Models and Biomarkers
June 10, 2019
Trained and supervised by internationally recognized experts, we have acquired skills in a variety of inflammatory disease models at QPS. Such models can be…
Accelerating Pharmaceutical Breakthroughs for CNS Disorders
June 5, 2019
Although we’ve made great progress in our understanding of the central nervous system (CNS) and the disorders that affect it, CNS drug development continues…
Skin Biopsy: A Complex Model Exploring Gene Expression
May 9, 2019
The heterogeneous presentation of clinical cases and the complex requirements by health authorities and care management contribute to making the development of innovative treatment…
QPS: Young at Heart
May 9, 2019
At QPS, we work with a team of Research Physicians, who are all young professionals pursuing a career in Drug Development and/or Clinical Pharmacology….
Meet QPS at the EAACI in Lisbon
May 9, 2019
Professor Zuzana Diamant, EAACI Asthma Section Chair (2017-2019), will chair and lecture at the EAACI (European Academy of Allergy and Clinical Immunology) symposium in…
Meet QPS at the ATS in Dallas
May 9, 2019
Professor Zuzana Diamant, MD PhD, Executive Medical and Scientific Director of Respiratory & Allergy at QPS-NL and Khalid Abd-Elaziz, MD, Principle Investigator, Associate Medical…
DDI Studies: The Final Frontier?
May 9, 2019
QPS recognizes the importance of well-conducted clinical trials on drug-drug interactions. Historically, the CYP450 interactions provided valuable information for the safe use of drugs,…
Challenging the Inhaled Allergen Challenge
May 9, 2019
Presently, the QPS Respiratory Team is making progress on a large data-intensive, 2-centre allergen challenge study in eosinophilic allergic asthma testing an innovative new…
QPS has a Strong Competency in Alzheimer Research
May 9, 2019
The results of a research collaboration between the neuroscience group of QPS Netherlands B.V. and Professor Peter Paul de Deyn and coworkers of the…
QPS will exhibit at the World Vaccine Congress
April 15, 2019
QPS will exhibit at the World Vaccine Congress, April 15-17 in Washington, DC. Please stop by our booth #600 to learn more about QPS’…
Costly, Life-Changing Type 1 Diabetes Drug Delays Disease, Receives FDA Approval
January 16, 2023
The U.S. Food and Drug Administration has approved teplizumab-mzw (TZIELD™), a drug developed by New Jersey-based Provention Bio to delay the onset of type…
A Breakthrough in Converting Brain Waves to Speech
January 11, 2023
A new pilot study conducted by Chang Lab at UC San Francisco has demonstrated the ability to use new neurotechnology to enable paralyzed individuals…
The Modern Quest for the Fountain of Youth
January 9, 2023
Quests for anti-aging solutions, usually the stuff of science fiction, have been revived with research into cellular reprogramming. More than 15 years ago, researchers…
Attacking KRAS Proteins to Kill Cancer
December 14, 2022
Recent advancements have led to the development of new cancer therapies that target mutations in KRAS proteins, which were once considered untreatable. In 2021,…
Offering Pain Relief Without Opioids, Vertex’s Sodium Channel Blocker Advances
December 12, 2022
Opioid pain relievers are highly addictive, contributing to high rates of opioid use disorder and overdose. According to the World Health Organization, opioid use…
Children with Retinitis Pigmentosa to See the World
December 7, 2022
Retinitis pigmentosa is a degenerative eye condition that slowly destroys the retina, the light-sensitive tissue at the back of the eye. For Canadian couple…
Introduction Real-world evidence (RWE) is accelerating drug development by using routinely collected patient health data, known as real-world data (RWD), to deliver insights beyond…
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
NEWARK, Del.—(BUSINESS WIRE)—QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in…
NEWARK, Del.—(BUSINESS WIRE)—QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by…
TAIPEI, Taiwan—(BUSINESS WIRE)—QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services, is pleased to announce the expansion…
